股票代码：300111 股票简称：向日葵 浙江向日葵大健康科技股份有限公司 投资者关系活动记录表 编号：2023001 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 线上参与公司 2022 年度网上业绩说明会的投资者 时间 2023 年 5 月 11 日下午 15:00-17:00 地点 "向日葵投资者关系"微信小程序 董事长：曹阳先生 董事、副总经理、财务总监：潘卫标先生 独立董事：刘国华先生 上市公司接待人 董事会秘书：李岚女士 员姓名 保荐代表人：周祖运先生 保荐代表人：张天宇先生 1、请问与其他跨界做光伏的企业相比，公司布局光伏电池 行业具有哪些优势？ 答：尊敬的投资者您好，公司的优势有：其一，丰富的产业 链资源优势，公司自 2005 年设立时就开始经营光伏业务， 投资者关系活动 在光伏产业已积累了十多年的经营经验，拥有产业链上下 主要内容介绍 游丰富资源优势，这不仅有利于公司控制产品成本，同时也 有利于公司未来快速释放光伏电池产品销量，提升产品盈 利能力与毛利率；其二， ...

Financial Performance - The company's operating revenue for 2022 was RMB 335.86 million, an increase of 12.97% compared to the previous year[5]. - Operating profit decreased to RMB 5.91 million, a decline of 89.15% year-on-year[5]. - Net profit attributable to shareholders was a loss of RMB 1.14 million, down 102.13% from the previous year[5]. - The subsidiary, Beid Pharmaceutical, saw a significant decline in net profit despite a 13.14% increase in main business revenue, primarily due to price reductions from domestic procurement policies and rising costs[5]. - The gross margin for the pharmaceutical products decreased by 15.01% year-on-year[5]. - The net cash flow from operating activities decreased by 75.66% to ¥24,157,571.67 from ¥99,269,612.43 in the previous year[24]. - The basic earnings per share for 2022 was -¥0.001, down 102.08% from ¥0.048 in 2021[24]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a loss of ¥785,242.97 compared to a profit of ¥3,808,918.11 in 2021, marking a 120.62% decrease[24]. - The company's operating revenue for the reporting period was CNY 335.86 million, an increase of 12.97% year-on-year[54]. - The cost of goods sold rose to CNY 239.57 million, reflecting a year-on-year increase of 27.71%[54]. - The net profit attributable to the parent company decreased by 102.13% year-on-year, primarily due to price reductions from domestic procurement policies and rising costs[55]. Research and Development - Research and development expenses amounted to CNY 14.19 million, up 15.69% compared to the previous year[54]. - The number of R&D personnel increased by 15.87% to 73, with R&D personnel accounting for 24.75% of the total workforce[72]. - The R&D investment as a percentage of operating income was 4.23% in 2022, up from 4.13% in 2021[72]. - The company completed several key R&D projects aimed at product upgrades and cost reduction, which are expected to enhance market competitiveness[71]. - Research and development expenses increased by 20% to 150 million RMB, focusing on innovative health technology solutions[186]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing industry, which is expected to face both challenges and opportunities due to ongoing reforms and policies in the healthcare sector[36]. - The company focuses on pharmaceutical formulations, with a strong emphasis on refining and strengthening its active pharmaceutical ingredients (APIs) for anti-infection and cardiovascular disease treatments[38]. - The company aims to expand its market share by leveraging overseas certifications in the US, Europe, Japan, and South Korea, while improving its marketing system and brand building[92]. - The company plans to enhance its product structure through new product selection and project initiation, while strengthening R&D capabilities and optimizing production processes[92]. - The company is actively responding to national policies promoting the green and low-carbon transformation of the API industry, focusing on improving preparation technology and waste treatment[39]. Governance and Compliance - The company reported a significant improvement in its governance structure, ensuring compliance with relevant laws and regulations, which enhances operational transparency and investor trust[102]. - The company has established a performance evaluation and incentive system linking management compensation to business performance, promoting accountability and transparency[103]. - The company has implemented a robust information disclosure system, ensuring timely and accurate communication with investors[104]. - The company has a clear organizational structure with independent operational capabilities across its various departments, enhancing operational efficiency[106]. - The company has committed to maintaining effective governance and timely decision-making to protect shareholder interests[126]. Environmental Management - The company has established a comprehensive environmental management system, complying with multiple environmental protection laws and standards[152]. - The company holds a valid pollution discharge permit, effective from October 28, 2022, to October 27, 2027[153]. - The wastewater treatment process includes multiple stages to ensure compliance with discharge standards, effectively reducing COD and nitrogen levels[155]. - The company has implemented an automatic online monitoring system for real-time tracking of wastewater discharge[156]. - The company is committed to continuous improvement in environmental management and pollution prevention measures[156]. Legal and Financial Obligations - The company is involved in ongoing litigation with Jiangsu Zhenfa New Energy Co., Ltd., with a claim amounting to 46,171,177.33 yuan, which includes interest calculated at the benchmark rate[197]. - The company has a contingent liability of up to 22 million yuan related to a guarantee obligation, which is expected to be settled within ten days after the conclusion of bankruptcy proceedings of a related party[198]. - The company has been ordered to pay 17,692,345.50 yuan to China Bank, with a deadline for payment set within ten days after the judgment becomes effective[198]. - The company is actively managing its debt and legal obligations to ensure future growth[200]. - The company has made significant progress in its financial obligations, with a focus on maintaining operational stability[200]. Shareholder Engagement - The company held multiple shareholder meetings with participation rates of 17.80% for the first extraordinary meeting and 17.78% for the annual meeting, indicating active shareholder engagement[108]. - The company has not engaged in any significant related party transactions that could compromise its operational independence[106]. - The company has committed to ensuring that the interests of the company and all shareholders are maintained[168]. - The company has established a commitment to ensure that the compensation system aligns with the execution of return measures[183]. - The company has confirmed that all commitments made are independently enforceable, and any invalidation of one will not affect the others[184].

1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 浙江向日葵大健康科技股份有限公司 2023 年第一季度报告 证券代码：300111 证券简称：向日葵 公告编号：2023-039 浙江向日葵大健康科技股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： | | 本报告期 | 上年同期 | 本报告期比上年同期增减（%） | | | --- | --- | --- | --- | --- | | 营业收入（元） | 61,283,853.74 | 61,125,009.58 | | 0.26% | | 归属于上市公司股东的净利 润（元） | -12,361,272.45 | -6,972,862.62 | | -77.28% | | 归属于上市公司股东的扣除 | | | | | | 非经常性损益的净利润 | -12,582,752.52 | -7,157,886.70 | | -75.79% | | （元） | | | ...

证券代码：300111 证券简称：向日葵 公告编号：2023—041 参与方式一：在微信小程序中搜索"向日葵投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"向日葵投资者关系"小程序，即可参与交流。 出席本次网上说明会的人员有：公司董事长曹阳先生，董事、副总经理、财 务总监潘卫标先生，独立董事刘国华先生，董事会秘书李岚女士，保荐代表人周 祖运先生、张天宇先生。 浙江向日葵大健康科技股份有限公司 关于举行2022年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）已于2023年4月 26日在巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022年年度报告》及 《2022年年度报告摘要》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年5 月11日（星期四）下午15:00-17:00在"向日葵投资者关系"小程序举行2022年度 业绩网上说明会。本次网上说明会将采用网络远程的方式举行，投资者可登陆 "向日葵投资者 ...

证券代码：300111 证券简称：向日葵 浙江向日葵光能科技股份有限公司 投资者关系活动记录表 编号：2016003 | --- | --- | --- | |----------------|--------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 财通证券股份有限公司：张成 | | | 人员姓名 | | | | 时间 | 2016 年 4 月 28 | 日 | | 地点 | 公司一楼会议室 | | | 上市公司接待人 | | | | 员姓名 | 杨旺翔 | | | 投资者关系活动 | 1 、公司硅片产能 | 8800 万片、电池片产能 600MW 、组 | | 主要内容介绍 | 件产能 800MW | ，公司目前产能 ...

证券代码：300111 证券简称：向日葵 浙江向日葵光能科技股份有限公司 投资者关系活动记录表 编号：2016002 | --- | --- | --- | |----------------|-------------------------|-------------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 长城国瑞证券有限公司：潘永乐、李志伟 | | 人员姓名 | | | | 时间 | 2016 年 3 月 23 | 日 | | 地点 | 公司一楼会议室 | | | 上市公司接待人 | | | | 员姓名 | 杨旺翔 | | | 投资者关系活动 | 1 、光伏行业趋势 | | | 主要内容介绍 | | 去年下半年增量较快，受电价调整因素， 2016 年 1 月 1 | ...

证券代码：300111 证券简称：向日葵 浙江向日葵光能科技股份有限公司 投资者关系活动记录表 编号：2016001 | --- | --- | --- | |----------------|----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 太平洋证券股份有限公司：雷强、刘晶敏 | | 人员姓名 | 华泰证券股份有限公司：何昕 | | | 时间 | 2016 年 1 月 14 | 日 | | 地点 | 公司一楼会议室 | | | 上市公司接待人 | 杨旺翔 | | | 员姓名 | | | | 投资者关系活动 | 1 、光伏行业形势怎么样？ | | | 主要内容介绍 | | 国家能源局"十三五"的太阳能利用意见稿 ...

股票代码：300111 股票简称：向日葵 浙江向日葵大健康科技股份有限公司 投资者关系活动记录表 编号：2022001 | --- | --- | --- | |-------------------------|----------------------------------|------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | √业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 网上投资者 | | | | 2022 年 5 月 11 日下午 | 15:00-17:00 | | 时间 | "向日葵投资者关系"小程序 | | | 地点 上市公司接待人 | | 董事长：曹阳先生，董事、副总经理、财务总监：潘卫标 | | 员姓名 | | 先生，独立董事：刘国华先生，董事会秘书：李岚女士 | | | 1、 2021 | 年度公司扣非净利润大幅下 ...

股票代码：300111 股票简称：向日葵 浙江向日葵大健康科技股份有限公司 投资者关系活动记录表 编号：2022002 | --- | --- | --- | --- | --- | |-----------------------------|----------------------------|-------------|-----------------------------------------------------------------------------------------------------------|------------------------| | | | | | | | | | | √特定对象调研 □分析师会议 | | | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | | | □新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及 | | | 交银施罗德基金：王青雷，北京永瑞私募基金：陈志，华宝 基金：刘文正，明泽投资：张鹏宇，太平资产：陈 ...

股票代码：300111 股票简称：向日葵 浙江向日葵大健康科技股份有限公司 投资者关系活动记录表 编号：2022003 | --- | --- | --- | --- | --- | |-----------------------|----------------------------|-------------|--------------------------------------------------------|----------------------------| | | | | | | | | | | √特定对象调研 □分析师会议 | | | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | | | □新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及 | | | 安信证券研究所：马帅；上海睿亿投资：楼鸿强；北京永瑞 | | | 人员姓名 | 江雪峰、林赟 | | 私募基金：何山；上海人寿资管：莫凡；杭州中大君悦投资： | | | 时间 | 2022 年 9 月 2 ...